Qisda continues to expand its “large fleet” strategy in the healthcare sector, striving to achieve its sustainability goal of having over half of its profits come from high value-added businesses by 2027. At its shareholders’ meeting on May 29, the company approved the 2024 financial report, profit distribution plan, and a cash capital reduction proposal. Consolidated revenue for 2024 reached NT$201.7 billion, with an EPS of NT$1.11. A full cash dividend of NT$1.11 per share will be distributed, and with a cash capital reduction refund of approximately NT$1.80 per share, shareholders will receive a total of NT$2.91 in cash per share. Regarding exchange rate fluctuations, Chairman Peter Chen (pictured standing) noted the difficulty in making predictions, but based on industry consensus and market observation, he expects the NT dollar to hover around 30:1 for an extended period.
Chen stated that Qisda’s healthcare business generated NT$26.3 billion in revenue in 2024, a year-on-year growth of approximately 7%, accounting for 13% of total revenue. It is the company’s second-largest high value-added business sector. In 2025, Qisda will continue to focus on the healthcare industry, concentrating on three key areas: hospitals, pharmaceutical distribution, and medical devices—injecting fresh momentum into future growth.
In the hospital sector, BenQ Medical Center aims to become the leading private healthcare provider in China. The company has already posted relevant post-hearing materials on the Hong Kong Stock Exchange’s “HKExnews” platform and is expected to accelerate its progress toward listing in Hong Kong, hoping to leverage diversified capital strategies to support the rapid expansion of its medical services.
As part of its “dual engine” strategy in medical devices and pharmaceuticals, Qisda continues to drive innovation in the medical equipment sector, focusing on differentiated products such as hemodialysis systems, ultrasound, digital dentistry, and operating room equipment. It is also actively expanding into emerging markets like Southeast Asia. In pharmaceutical distribution, Qisda has partnered with Norbel Baby, the parent company of Ding Ding Pharmacy, combining its own technological strengths with pharmaceutical expertise to scale up service points and build a comprehensive healthcare ecosystem.
Qisda emphasized that healthcare is a key driver in its transformation toward high-value operations. Moving forward, the company will continue to promote profitability optimization and international expansion through technological innovation and strategic partnerships.
Resource: 佳世達聚焦醫療發展，三大主軸注入新動能
